y_80?mBLʴtbڧ@vIl'6ے@y!H::::뛷|ot(=YA(}N$ĝLauY$3/( d$e?uu9fG7G< fa·t'N*7nS?X>e2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1ce2E+?AW \}7]ħ/c5&nHgnPcbDn,uiv787MЛ{WaAWzh|1묛_5ۼ,7C;]Y~ਫ਼uz-hl㤛}= I4 -ڍn֙Im{b|xzՋyy ӻW!x+m?~HWj䨧Y?׺PMvl{_z39"sW7if mh"iߣݰu~ލga4it fio0m| a_ot˶Z؄U7gz/O#L7*<<U,Ӳ_i{;18n>N[qp{^8# <'LC;i @5^w5Cq3XӅQ,`'Oa޳MURUE ᦖzZT)zz3<@ʀ+uQkU1D'8_g:OWmFOUbpXtwN6 xND "i-ﻳjF>] _+v/Cd얃)~/o[F6NԃD_$sq 4T/{ćspz,HAk`[)Xgs|=kV=9b4-OuМ'Y *?'5'?}\M~^~>^^էWP`ӣoGm^4<^OѧOWw^}j|>|?|8=l4@鳛_߿:Fف"d_V#0 /F#ԋ!R`uMF׽tc.9^Lp+X&3n `d{^ݾ4y޼hܾnqCOX_TWfϧ>_gW/ێk¹ۿ{qfΐ8Kܻ]ptLvDd=%hL7 Z9إx ]xcRQ<~ U7j8"KUy Qhwz9u,O[f0eyNz>@1Q/q鍝Ah#/O[xo >́BGs h>aw7RUp|3r ):h^޾rWcuj0d7K^`г=q7w—Ij5vzz?DDyp;T*^|Po>×.n0Ӌdp}mw>\ ^n@&&$pdC9Jvv:JkJN^oZSi1lޟ緯F})-h5gˣ*< [nޟۣgCut,ޢl7@gHTq}q1r_l/Z5_*Ŵl[w[%$قilsQgaYz}U|ܟtEa݄-6SRGԿ>[2Vy3w8T;Ço㛳侉bwspc\|!wԆSu]l7"=?O[`.d>6>}ξ_[׃eOB t<\܁!>?L hݱ3CrL[#Oun8y@oO%@!mM%@;C˻![)-؍5 5h?mmo/a jӰ'H?S?bƛOdvZ "`{|ZSx߾ܢ! |B]S|{5$hy^ma+OGx ]Cp\cy)3(uAD]LZWU )m"= G3?̈is(]890-Ru'E)wj [^)g+DUN!D";Z}uVBVQ%O#XSHGd ,J+c&U<`J)d rBIA0:ZZE<%[1׾1)6~l7Ҥun1rZ^.-v e.3F1,HhzpTο}Ro!B!#@,wp)+[/wMGs]mփޠ"{ϿAvh]zsB6ltAlN_[GLJޛz1G${>oݲ&jESyM,GŁ7ݿQ{p`r¥zAUї7^LQ} M/Öu`E> d~hb`⟥M ѿ ߫աG(Wr>S͏N|Kwo~OW~G yܛ^kIz\Wgei" 0Φy8Pxe!ӿ >r/O%S"ʑkI}0$8U{ί~#y_7H464_o/lUa.Bxhr ,#.`s2"@ ;dpo"tDB̍e[;| og?rF?~p:/"POFq'do_!,Ӌo0f2Hh8dmƓ.b/?_.>&J/#׫!ݥ~+$ #;=dVDQ:wj!XsC|zU^{+}A;L4<&X rnGx ԽQ\m DB(Gp)2B'D` +`Eh2S5@ $ʗBڼ]f`ТcK;t{;@ůؙ<2HZ,1(X~߾ղataP=p_dJ "(waAW5UDJmDKH3 !S(tNnDeKԺts|.Tp޼kK] fzR26AZoTۥ+(P]g!Vh8,T&2H41-;䓫@uJ"(4Y"׋LEVI<+^H˳}}M}:OrQk.e_m1yȋQ0+Zֳ~#PQb_>Wfw;8Z \>L׌cߑvCOA0.MkNwvwp^din`cn3~{@A<<~3/>h";ez;q0dewKVbyЉt1Y4n5.Dۂw1yp^Xm&$~1%#Ge}{;1 >~lL~U bPvTv8q1nƗ1\|K?]]4/goo^qpl?~ǩ{{wݾ}5?xws_}qm0lWۋ yS~sKkS~1/A<9]n_-^Gj_fo/OͷzyvpJMj?&TS=oo_OE Q7bc^<]H?$?o_p\wvm\K5c.I־?2MFw6< }S η׬ݔ.G`?n5>* .M!pؙ^\tnmվm>/6Ҍ>AqTß~9Ylmkᓷo϶7ߖcWϷۇwmlH٧oڬםۑ_zpexN^Ƣqӻw4<~+ F|n>pZ=}y,q}:X^_oη{ip51@tWF|?_2:mޚ{\w||NF|x{7:@䫱_;}?|i>{u|u4ikAGpuy>FtPS_ﷇ?a}g>׼4foFPSeOS?u|x9yuzc}o_mL_<4 ; ozp|ܞl@X_HwyH!=<{QI?ڵ''3~}xvspl;ip׌tW6}k{K|{C\V? ?޾LhponϽ7}!xxp4m^nxr?u^_<_~y}go}l]~noO'߾w1^|~ټ1_߽tϫw7_/QHg?O#BWaL>}v.no?4߿ťw]|pxL_'G|t~239_wY7NRhEyp28h=k|wο؋{ʗ_}u0 OwשQWft^uCӧoo3ř?ߏmt9{Nwξ]: N/7adv+I&<:o\%>ޝݷƇo-A̩i:_| $|}i{_^z}]:TpԇC'so{؎ߙO=ܽ w߃_k\_pniK8͋ӷG/ywq޼zVut޿͎ճwҷ />4GOQ:7^}[BK^4ۻZ|~;R_;/'Io$>ۜ}|z ՗އ%uQ27kO +/>|3^iTJdzAc[w0H>W׃ Qw~0epuvxx~|4ۛw};pZ ˯óai%R)x}R%`E^5lh7?Ķ d/ :`A:W/'=LLg7NdL8)VGn]",얚wfhUvas]_}.y%'}UN5> e^Us0b yPbJ-ׯo/ ڞ}{,ooorT1%y`\hJ`4jx'e5ɯ^$;x&t Xڶp/q8bd3]4yK壜3S]4Dd9]9̜V`8L "wR< .7gJMl}rl?޶\KXowAN.pK&< *o9y;M/,\`ULZ*UB"ޔg}YH\el2G Ɉ53 [7+Px)ࣰ>Ws׋,3Xl&\:ſn{pq&'܈_Q]}b{ >EzZi+??TM*eNSlswAޱ+طw& Lr8P\3ߊȧt2KwQ|y7 {z?~ޛw%g::h@gw)t^=&[~_Ƥ0N~Gһڥ͆H*œ I)tWf{:$X%2+,{A7p{`+/jVm0I&AP8_u?QWIK"KX_zphp{!iSi/66W747}/qCչss$P뵤UsFwUt|RoNN$vojޏDBQGAX1:MMJV1gԠzV, =W?M;j83cT}g5{{%Ff zۉeo٪ zaw(<ɢיOMEm9eò&ivo1)̻ZG2_[5_QKOf0N"Mh(VW^搪 I BwPg'Un4$iII{ 4h5qyN& S/f+Xi#|;eޘ1T{Z gѴ;ȏ^XshG܍aw &C괾{EF]?J#;ƺS68G;n.]QHmdkgY:|o"_^4f*jz4 peo~KoR߿;.|WZ hIҫׯ5 ޝg=vӀQ͝W4qfic {rka*tR-Iu,l-K9evMY{/PuM@yQhT[3y1V}c`iC/ci0H;Ad8zV6 mV@\g#+|R,D,J=+P{o9Dy0)`h J>N ͣ`IvXK&'(e4U۶L4,\?뙾uFZ-,cXM%Ղͼ ˠN{ןf0wC;3S?\ e "ˤ4D>_.@;c8M](H<݄e:eۃ!Ī/8nҚK~sXF(Z~_,kckM«OWwATSƉ $^ڦ$'1n*N6["&ݬOBG.9-:%r횛Buu1ݕ:Жrϭ7 kXLfV6މڮ ^w͞;bX`bހ4 F?eQOrjM95֒3z6]rUXYE2cyK+{̍h؞3>@ף~>,MIV2X9K&v*!{ zͳd[߬gFb#+ e mljL`]@e$؍ߧ_;?|BIqʪ`5w |ɔXW1Ĭz5˫ !v-,dkXc%@q6]̽\o8 7@ '`k/;*u R%/[m$n&ĿC~ݤFWu84PFuT Sʄw?өO2̼6$?='?S^żIW` COP*/IA(G\!Zx(hj!;`M gekaMtd [I Uȟ`q~Ӌ?iTu DE\$r`rkѺTSж\mhDY`)+!¾;/ٺۛm#7lM{U+pp0v68mI2M]#P0ó"`^a&]=pRhj¿KEG;fr ѭ6'h?^S5Wvo`,azBiZzab>!Zw,";ail>u 1T(V "QCPyw!,xاγUiP`7^#nU`vaydK1W!g3""Gs3%|D!&° {dt"R$2?Hg"UhKWQȒ  +kUD)"ĬT P rUWIh=Au o0f"w ȍ0XSZE+*8رrVc9b6UX0X.܍U1t+'Q=0yBCm)R¹Y !Qiy˅sϝ A)sJB0n;0RQTN 0nFeYoleSآ(2oꝺ*jUeO(vVa ,"5ta8^_ \pRY4&z/ YF+d \ l~UA`o DZu]-Hߵrjv& 񴓢ЁQH,bo CD{"*C⧜NaW)N;[+jUK]32W);JMMAk,%W( IS~\!}h6Wn.axpXyܥ*2stt0X`f ayq3Kw*:cGN德JtyQp A8lt ke*X x;3^Nݣ؍c+RPMxm j♱4%-\F-nNԱrjO.*&ln2!PnߝFÁtfgޠ~='zDAF;4ǹTNMM"HEN '.Z'i `x&*=n6e8ȁMR ,-8l=u?pׅn؂4[+c9D&Ghj:6qF])/a쫇WXT K]8]̜`k 0Ǜ3ò63vp& QVeZ0 p"ڵM,R.tu.6y섮д R] 7ҹogx~vj4r5懗AܙRviu\aQ%Nk( Lƻ5_[ơ=G'T1yB.?'AuI3gcm|j˩NL%#U4*5)oSZNuJ+\/p GOVc, }z oI\dMGj:K@-.bhNt#m:kl5Ks2[.N/ljfLQ4ռK.4 r"nՑyV(Q3b.Z ׁ\(3Xӧf!zBQg)RL67.2v7"1ji`uzq{8~x#-xf2j㷲?#\1?dyj ,7׃F<0܌l^#, -@43E 0] }UxMm&Rs؈'?Xۼ+Xm{p r7wxE^-̷jw=enbtMМC4ᖉn(jt:|͉<{z!jfy'ꆃ -uo{'(S~e+* -Yvys{(fkc4f/eg 3ڵ*h-%?/;7\(HOSgN WPzI("n6 tRUߵh0;ݾmcS;?.UPL) 1uu'TFUj!5^onu9ݮK9ϖxE-Sč „{ M-rk D,7==  uQB_ϝBD` Sx^ט}|މv; (pWK<\X<$,e]jZVo6&`ywd^yd7bz-MZT#JQʁUvO}P`GYgMz.P-㞙jY긾*4'ذ;0Fnͷ_84QGz6F7P&]=oƮh4̣}yBU+WfU#,{Coڛ~W-o ]g⡐KƖFGsun0L ޮt*7'u%|+!oagjDR!ȳS3*iFU +o[qATgHEM+N (Cr*](Nf51O OSY)F{?  y^$^{Ya6_FH_ n}K3 +Q,U,;C–JKo%yL$|p}#4}0LVX )&YGeGIch2D \8" ZҊ ,5@%)7W-{E>h n`ě&ҲzhtVXlCjݙ5 M69muvģ/¼%0C*KocOF^VCOez"D$1?;`6v6ęfޝXzS7ڵ\׍돬Qv”8Rt&\DH`H ?ͩ8]A:sG &QK}O6TRrKµbaLh/$U=IRZU ΢TI"vh%`R&wʑ BjGbGk]aIIJJuIB47ȼ*|sy$Up^dN UE&賅K{Gb4‘w5`- -: yB+Z`Pfol3O MGfI!6#dqzWGx?t]uxn92ף!!$3IJ1? ㈓|FHYCQO&Ap(c?fؐ h?&!%2JFE47a b曟iW^CS -~釹 s; T&9wn6Mo&)ȴ67gz\NԵBdFl`>ll :vr #u *$}xqGd#uA8dA-bH+î,:4BOGN!ORh7u? >}N04v0:.1t:#G/D$6gSoF )1_9nԡw0mA!+8ƦaUu.[h8+&v\NA|urK2J+K)zd4[2oTtCa/(@x~g/@mnHV C7&k4qM1 ۝.{6v`؟ᴀ{Ù6Qr T!3³ʵ$`O #R3*OPe1p͖B[- :|-wHbiR$=N@̓LH[.\^Qمۭ^p{,FVWM!%TgJ׻Yv|q|TUz!z `Ub8N@D!a bGQ&A=bHiP&]GX=hpnFԫ[QT ᗩz񕮥fj'~*,f>_39JEK^U@A^6߳'*&n'AaN{D[ bGei,ҔUog_ hH >N++Ƃ_㪫Jeܙ)r433dЍO*)iAOIA2QNqWf M_Iݑ@}Hd) \6HLOiIxi L7$G:`imVpƃsƋ-q*4=A Tl24~< +8lTߪ=$prz9'au4mF:sC6Ul3V}H${khVk(CMNܬys4(+jK  QBSs; ķroѠ7Ri7+jnԩ(hNo@8тRB74{$RP]HYyO`l@vlHFǘ g`,%JsR&, +{%Tf jDPRϥ%DvMT,o Ng@A< -qP?dfd.!囝+T'Tfp˥6|W\Ffro)ӆSB97*;fiBsr-p], RBRPȠUoP!8m" 0U,] oί7C C)rN3v5HuJS׻AE>xJuE) +=Y!CXJƹBd]@ &i VQQ 0KM3J<3 )[OD/ J?7W8e􈊆xQE̍+,=:u] :˩Ab-(|ebaGeё%GZ7aDpϒ{ ʘM.D5D27LoLF"<ԋ̤Y8s־b$?ߦ ](UFn$#W'42|e h4P"wŃOUT~a>*1ExxaCk39jUedETSj8/$"o=5AU+V|RJL-F _dPz^\--hn$|" L%'Ъz@R&W{/_Hغ wf<ޢ`„Ap̓w{۫ bio]694§/XBVEpId0:VsgG|S6$t(;U GwI tNTKoh,A1i|̵[aS/-ӄG)4bWD$͑B'n=kË9 /!܉[y/ Z.-W1&:b@/rqZ|\pGȚ鞀lܡp>| L\M-9K.-Ex7]W˱v070؛(dmjܕVFG1ej6Gulo( {TIb^ sMSF 59\st[+1{)َ'[el׀3tz:Bea!$ #d t|}*Bǀ%9"{{57ڸQtRY3tۻ; " v9WJXHGs[p~X2nBv=뵸IT?'DZ+Key,T(L۶c O [pP} U,D*b첥e# Q9bu"1TJxYĈQYD-hbq;1Yԋ\fr,RzsIOI/#"Z4t,u5b:Kg+1ʉsg64cbREAyRb@ϮM- kiGdy;(2-.3 )MVmɵybD GfKxS5|pbeƏ$¸q.4 |a*_/Khw_]WLNRRPQZ3-kI]>%?잔[T{~DY]JK%l--Ko-;ipAGNdz;CYدjÒ'nط'"kSYd#] S7wn /]?nЗH ^i,_ѐh[_ZEFNtG]0RԡUYFacnArO Q,,a\s5Ur7Q^2tY̜M=U:*( < %z:Q %N kcs=y{a3*'6A{!,E4yo6`މa {{cWo%̝XN5Kuv'EfYs(p:Qެm1M*._vebztbIط˕ ( i>#_?]aTyQDHd?p0G3\M#f4a8s(]d`Zn+v3E2q@]))t`"w "aߥz +N^D/DL6J)J۳OId8sƙ5hp:feRuc$Yg% B,7Iu.' m`_hcpS;icEHÃS.:vXGr>ˌMGF0k``]c5`򝾞x6 kܕ={DGXkf訴Vvę &,*vmi8]q!{]u :Y;Wþ3A AXGob&go{{{TJ0qTpZ5FM`ԈȈwcϭ(`ZƅmIAMCwW|3h݄wJm.{T@XlU S&)p6iա" |(4wG)?+cXacR/Zu 81C]G.q͏aEč_~ݶb Z-?Ł871%%߿) r@𕃡͐jֆ`EzWǯ6[diG>^PHTF>LUYU.ɢkd5!qr^xiV6i38X4x-R;7"`Ul#CV}Miҧ1 ;raOBORL2r4(MñAK!uJJ|1AleeQ"vh*yLCp(B9Fl\GfI+ Im1_gY;4(/dpJWf# k`U/u/)?YU ojCugX2HX56' _(4ݡ[bl wsZ/8ƴ;)GN䀟mlL5ʅYבؠ,AD'0qzQ(SYZ0Q_Zn_?代f±٢X^jhAYk D cKeCs>]*j}ǖ᯽X$<)ГułzP{?wk6 /øRO[7UY8J]9KK6O_њՂzqt., P±k y>+g؄ڸq ĤzV;DZ@ġgj&Nu-8`|zy^dQ&!?/A89諁cV/>Pтm:lÂehݏ|uRg{{Ro˙g_y$q]!zQmPR FmaMV+,"(9F\^xܐ w>y+efҟ#gj(XBuU-=R5<TsS*:5#JV5np6Bwkz)Y V&< Е SnSN-}扻E+ Z⮟mi^-l0$_. lʸLBKI,"8'C`r{!Ig9ӔQ,憶I,{M`rTh86h}7>EM]Y[ǚ8٨%!NN!cU9"#-۲s3n8@nz9e1У(Yo6u s-{0 ^rTa@9,֪s6fi"6&_a'tHtPt2!_y92 ӑ[B-FUhԴ‰1U s0ND"W A, ȁiSwi֙\*\q".G#Tf۵Nƙgq (M,̔rj/ U7[0`ot</3qF|yXѨd&ӡ0מ2޹T2FMǶz:-Pt 6`1簕/NYB@± s`aOe^M(|2{(3<<bܠyF}OPNFJktg[C7sKT&쮞x= W nn-oCe@+]!;¡7p&ahMIFT9єLeMx CI(m { \ˣ4SdX8NY&GxXÞcIh5vd`4Tz~Zp˱; 3l`^q+2˪Tܗ+,<p1P3OĿDN$"j`x~'1g3&ݝq r! ׭gRwb1k3B4!h>9I7eg>toƽ&WG-NJ\係^&Y"98]A.砂P*c`jd&3FIf *h5l^ .>y&Ѥj~ 32CpNFCM@f3] H s5*Sa"TAZyOy}( eе8:5reh`o-j%~9yǗX`{*K Kw,*Kk@e<溨h|Y@XjJ?-}G$T%FύDŽ Y!QN??׀'ځ^n09w'*2r-'f&(ݓ#S۵^2֧,]ΕAiGq8wDqo$ӹ!GQqhdFm[9yO Tbiגq#6\9)l<v,sЃSlv*jVIRJa^b ZEz0 _AIKMnIݺQ/HrU֏Dz(n4{,&[M\WF6w5 u +G5n kxrDQ*ڦe\)irB$ LXz'Bs%!5Kt[`폰 kIxQwl\j`uW(>ODVb_K̵{tWܠ%iԱ껳i\3OJ,}no&:`eF(ȟ PwQn3vIJz BG:vf'#s QJ3O߱Lj eF!xRxU+|afTЧrXc pyk"VݠkCAQ*S@)LUȃz; v՛vy͇xLMGr 8h'WmcQr]Yv?ֲ(zOkz;Fv|yaY;~4>'ГȖ~2!"$ ((2g ](nNSc.fJ 4V:I7w4=}DzmϷSqX՛#@#{BOhm䁊a &Pmh@CGv-:NuZTgix”<4OX]M U.80t!Vn&]5NL/xz*jqx-~m"$Ez,/_I'nDJ8ؓxBͩىNtXu-=?sr8si.};zAZ4uQα3'*[z<⺯y%Nj#JqqԵBTIWu2 >}r@n^;A|w%* =G4j|0ŝCQaZ%k]zļ79Myt_2XfI-=6سYu/ce3r1v^XÅ{JT<499tp]"Y 2v?_*t`zm(e^7OK<\#OEt@{eD8% !A3싍X]$s=&&#x؆Zr/%,ԋvcs#ĹJ2x%@kRQHA*CDML-;q<ňN!n%񷮍hVOuM06TLHo1<`zu L&0cŪTyNy_!W(qv;o䶀:#ui2mv;ei`O|ltCc\i"#$B\ݵgXh$J⮉3ro! cNBJk¿Kl2Śiobdu|ӒjT]}_ lZ.*4A !<ңp^?ќMB:b:Et(E~-<<2`>G÷իibΝVM%Ǡ1Ǜ(p:׼I/n#4ogImSNMJIff50ed}lakDC$ @~T6XtgJ^-* ődwF8ßqH(F.~wY#^[lG:Bh9F SVMc>6zQxK -n:95&w"0qqqL_*Ld}yj0＊ Qî]iRg2\nƭ͉p]wM5Q䆴c"Sp緺ZHY~LU˪ǔ$\xf]qbHtt ;&gyH14 ulW?i#2Ƥ_OBE"TlL&KT:\Ѭrqצ$?5[wZ%w7YZ$˹\ӮI H&]=a!q}UK*'wu0AOd.%F3)U=<.4AJNJ_;VI7pvJ3rYEky35AD 6 <{w6$200]˲0z_f\@Z+K7Q;Ù5B~xeidn|l6F2Rщ-d9j'fg3Y,'[~^nе'-^NnǁNbyJgzPZm7FHK@k@$Dʥ]k4yU"hhd5AXV)sn x9FQyXJJ\|L*ZVz~XMӊR:$%sy v1[1+D4wt(KʏЧ`pG(~@~w??6h઱frrk*-op~R %oG܃6g'>2B,s&hZž_)twXi8]fmYo[Sݣ`4JWJfY9ݤ~| f%ݭi˅ꆻ͡Լ|-(k^mre0]*OgGcS~9@zdZԛ3}Z.'\ké2}ul"ׇiFk+]KbNF4OqB,{'K+f X*daF[HY*<`s*` B]^؋ u}R>6cO< 0wzqSc s|bΖ3IôcXø'zH{ajESG5 QחL,7`L;c_a6aHp0{ .c`uZ{@OI'³Rǡ `-Civkyt7L] c`hrr=R{u4Jb_ڴמm؊kFoz״ ]@K*fux$@S+0`~1~Βֽ!2QYV* [hO"Z1Vy`WCMޕyUrpŁuƴ2/y "Zb%;ԝLQH_/K:A樌^fc]:j"L>O|jQZ.m+7Ы `$eUz:įO&E3:Q*MhT`۶'d<憙lQ]k9qc1t*Q(Ў]/\bꉦ3VsZ|m1Hm8_8.Y>XMy .կY٦nUDHXϡNs &>,-K-IvE噧qJ:嵸~qdWԒ`9bb'YLdUƊ\D7ȹ*HgƎml|񳦊vڎx S ܁M PڽJ<Ͼ )4]"G_¾Ld&jvNiq{̝Dka6BD,<%dCV_E FJ8 hH<=,1 Ex^g"эj=68R#4 涥-~INGpdm:,h?ė#C@n$)8X`l[-ADBэBG(@M׊pzgV5֥U"ͳvֽu)Jnj8*M<$8 3 -7<.Дu3JrӐ_X{z& ťN0,is uQXvDP*0ddq #?ڧĞPRCAeN v TV_dwĎ TG<5`%=5=n(zȯx];h xrʺf8UX׳pV ׎ל:@p`tRS?a¶籗mxeUFR/wpG1 ]m G4dԵKmn{2KN$̵ZdZjpP m"ljnG)WYƹDmtℹ4F+0_WF}~pc4WGÙFEjԡi) N~(wґ\L[$02 ЍW- 28&9.ڒZe[$+v*|ܪc-p,?td,f>gQ6&.j82I~Pr~m|OJ+N5D%c&n{T &LB@9^U~+2?T(/!C{EBa>WA#m(j2 ~7ML<&/- ֦슠/=knFWxRMN@t.sfӴӏ,}d$(` 2sgEI}1 c.1qDF}6Hd\qO#(HQ:,g2H<P^7v፪]LIAԤʣ`[U2R=b[˜|}(u}Oi7qRF#={khz=`!*RR,N٢*)t+lr,cB;AodFyj]}}3Mh> ֠tz E6 OV'T{BVUĐ% pIj &:0h׆QIiO 5N3eZRbAC}uWS " u:& WiwqP# ŝRiL˄2OJLFVv%Ϊ'&eE*[6_gYl >aIaP8V 8z-^̂ꅒRܐNaR:m\du%G魆$fr7 &C4E YM4]::Σ6W,ghZFh"C ^Ze9 v_ݔZU;ł?@i7En^x?alJ>JF>ƌLZ.Qt<7uSZt1r=XvS6=m`dv l|ŇGȇ/_'!2nMmRps:w"x:(G;GD7 -8iGjpBciqrC/S # z+Y]=9aV<ދ_n8u @: S ngVw y#-vegAlTxJlc)O|\D #g;CuSj>N`fvG0s t² Xen sXB9Q;zYdl;MהSf9RpL'\M=qJCje]s;bXˈg-n=y.J+:;j gi-˅#@%Y=:MbP_O ͢+:-(]ӂZ5{:̅̆ *l*RU!Ȕm /s͗Yn*g[6r-2%Zx!-x/۲#2m ʈ2q2~'Cse)I% 5Se{1Fé:Ҝu'L`ue9gl=ȆSFIC皑* mX)TW`hSl>/'`Ji7k%}ݑd{^f.H9*. q?YP >64,\?뙾uFZ)JRꎣ46EXGs-2_VIE ʲ8aqHd4s?\;!V/J{J4OÙެ<;5N3f$ˁ33h aj \-@Jzǁ% zkI˵) ͌\lHE36,팘"N!,WlxbݍxZːBv 5E8D6 c5:ݾtWE]iipm1SwTru™Ne ' A>\&{J[ۥJ} .Zۯ#C*<hUSs[(2}(SG?FIIX"i&Л jqwuVra[dX0O sUp$gv )s6QP"4=l?"zkkt):)(8.컛uu^ s@3cq~ <_V وf(@"AwH/h#.!0*UNP7a8=G+,Y-,:bnFzPXE 'fS 6+d%$8j+lj%'xOMU-mijHNV(eϋ?ps16Aޜ8"kˎi~iO$^;-tuUXjE8P`c4K#QA)Δ$UWf!Sf,Y-P%tda#M@8 soWGM``.=b)s s0T&^ \#+W@?1=gfxSukOD`!CB=%1ͻVq -=qQ>\ U& S9`\t@Vr~*4.tFXF~ţDΘhX_Vv?ƬXս+.1  =rǬm\ fh4U; BzلI"M\U;ܣ<V" .ηL3JNv͖ G. ܔd_Ytb}F+;2kz%_di0pZ~0Rx #$B6p"#1Ǫ$VEXq 0q*.&rN )?~~b4"hOWMG̹P:|B*rHFHuqݛr&jF" -%{> U$o nԍ%JY Gr2Շ͗dR5 }lm}&iL7X4K`rC>'R ,b6_j,84]Sf3Ls'D!4ylGxgf0{x5 "=UVoI1($*EgïQu&%<L[9:TI&ѼJќ-G+xA >-=TߥEq 𪇘"*!n6u\ NFqHBL0(jjM)VS tuL YzSuTF|! x4kp;fA@ }{Z6Z.u0LlO 4}ب'īN矋~t^Dϟwy{?:xDe?p+dmj2@-ٸW" Q:$ԟL؆t eNF)8)@Fn ]ɂwi/<x 4Nt3Ss"2`{Lzh#k:5 _k_qv1%w1EtIgdOfފc $]^^xnz g{5`L9 JgA`&|bz~S}e~6`^^B4}pCt7 1/DRl iVgߕ3@\ |#oP+"o)\|9{$^@jY/ج*э8N[wQyd;0)`S${`WtOq➒7oĨ52JYۦ޵XqT6. UAΤ638f1~YFnSQ;yL*Vqtޙ )v`ðT_~_yQaC4Ѕ7<)+: &eF"z.ēߺZj7C aP/KgLQ<D/@kP!1މo꫙@-1*0?׍Qi `}ZE"!H)%j Ze:86{sҋA-RRԟ> dkǺ5# cQ/XSJ{lZlÒgH(t;V}Vo0%>ǵHU L VRȏ"멍)j96\U;au6HxFdHVD o7 ,;s(w|D ]wʬU:q܅|=?8]d#Ow33.ce[5bh%a`ҤM$CCkAE2S̓b?ebYѢ%haOTg)[5 ɣnjV&NzN2'e|d-QY 7Z?}ᰄu4]#u)pS7 '"@I,9}t /:YX4^P j.`ʳ®kfr%BM ,*F=,&;0K4ثB yW;ّiǽ~Ux,8` f"SEt֬:im˓C]Z&?U ]ȞVBJ"cՓoV*$xD/G tK$6ȍ:fa8pB{o%:2ښ/,B*<=^O6l˧C+bivɉusZ%;Ҫ9\ҚxG~뉼7EW.r4MgvjCRe^_i3ZE'Gꀿ9LF uH:

М) =ڳ< =zTKb/E~dMy:~s\hyp6U\Н(EܰQ<#,fa2/T*)ȎXfnQ N})꼇*W74H~p0>3l_=Pd^-~v"1GLf”f;},BAG{2 ?/Q .zIAT }* C%:KNYhF.zFVګ3{~^ıF/kpfׅcԥ{FSH%0ns f^̖SdkN;ʻ%TrZ`2 R@VɼnbBC75_e`244ϦӺZ<LպD PyFQOV}i#7K 3_,el3AFn$>E $W#ݗH"Rx,ӒSx.+'ss;lqxxN.' ij m/4dT|Xnʳ k5mO)Gy[m<;cTBPt={EidҫMҢ2;")ivh@#=<v9'5͵˕҉LL(߃ a$t%s/ŚAO_*ͣ3Feu`E,K!|ӏ/bs(e_4 Ol%OlH{DUzXgƦJm}NtA odŦ!~5o[JxZowWy@΄.}?k͇m֟ &,eƁڃ4@yl@[ƲO>Rv uŝ.Mnn9Ԉ$> [Q+†O6xM,6uN4ABG(bSgJƤN#,ϓ>!a9d,'H0=}ZUqI߹EGBb+t'k@\%ہ)[ 4yG r}߀GLs7 y#EomitdQDSw /zyߕ]Gmke۩},S:䃄Jx,9Gj?[[Ti%8-Ub4$ B%$8BH7Vot:&>#|gM2f1 ہ*Do_;[1N}}=kvv <?UsُYcпh_bªY# =Hg JQcÝ0Fo> >*H~mTHDo4^~{??U豋[A>Nפk/Q[dFqqA T'F /S磖$.b!dSK}:hw!uw*XUst\֜>;l8Ѷ:bPW+Akl<0.`9"a:efӝř7$oh< ,u *"6$ֳ+3QGG7_}|H1tҍtJ(֨=O{`CN-Q̆wCO5 [Tpõ7^VeӐ!\5˻1qhLAІ>nK $Jn}F٧t0etY]~AU 1Sv9PK9 'ƙ'sYorZ-j`lQ~0T[8sͦ,QBvQUChRњ4XAl<}i ƪ@3r(b0f9xmz[lT6#gHfMf~:Z(pJs|Oم^bݞ }/᧟}#᧟#H}ϼ bK }=A\" @-mʀqwۺNqZ.tڸ (WX0I3Qg.~u~6Ab FCP1~yV؈Bby,- H;S/Z3m?J\יH_#߼w 6xt|yzX|3ᘝi[+XC0p~jGYꈒ^zϽ,_谻h?[R_v(YciSoծ5ʝIr{  Tx-̀oP-F^dK^ed0c0f|!|(/{r={2g_6IW d%E?pGm:r6" bxyzHf&LVnز[OHehxM"MUdP> 5TJ˭/M5Ǽ8 Iuk봴}gg{^=w:2f8tS[~mfüI-xN2A38ׁi6(J{I֣Mc- !T:ȭNH=Ic@D 1^!pp^[f^60БQuQDufS2P ? +[Zڹ^zfJGqA(tKߙYƫ+_:ZZ )t\t 0>)g_ϑ)/?[& Xd"5YWC:Q؜NZnzG,"ʥѫKSf2%zE:륷!P(M˷0 MyA1!EzB0=2%ozW2.kz(% 9pt&Ų1,"M͓os"˯T=sӖFÕ7y,xZ ~I\XeJz;H-Gm3MSMj4uXrX~]< Ұ*F>$(!L Xesa!gQ [¸1l'a.[ك[M.xAd8w& y,HY˨ud_f$NЫc a9e_$+P.LW c%愘 u}c㸜G 8#}h1FMpԸXU-sWFV:.WVHGo"cA)NU<}R)6PC*/Q9}w<:wk{*O:?t"r6|iNWI$ꁡ ` t"2n4=L<$q#pyMϖSnvTRdtu봩gw/}k[]'hQsO"}h pn y䘶VX_(жlGŖٖz kX `^'#Wsmqnz(06~6IOi*A:aE=I\6jD,;9pr]ؙL' wEjI"jQ-ӟi 5>h4M1E3pc1diBS\lj_/ی8  pqt~A)f@h ǁ\Fz\BVc ,)ɩS>\U[@ -X˫ݥڜՁyghDG8 >Yċ'zEI ʹdBbH?nVJj_t [`=7S\DF[S:LQ ےCvK gѨlEefyaKI B,zte|Hd'M-ugզd\6sv0֏jDt>y:}SYul}΅-tYr"40SW塽PUw n׮k}|ނpK\ | 6r .je4($[sګ_P)m5lӉYYR0ŠB[8"I<CQJCJ耵ha%ͺKhgtlF=ØgTa &\)ܐӍ'X?l].κ\ػMpL$;DcpN]1I9TGG~k>΢uygS1ܝgGļ*,?i7; b,S낊T^FS,yg8e}.eZWv.7Dڑv)5ܽߴ&AAOBaEce0tIX$SЖt]ʧX :hÉ# ƫͩt4z1^uZ_5W&a,lۘD-+k/Fkgy*izmqS |$ao3g+mm"y`S}8b tE֨1ɲ8;u| x^ZfK*# &HUGwE?_$x5'zbc1C{nBݭ H? lP,J ,c_ƻPu[TM,xcK?  C S,eܪ]nuIJ6޴AϧxaɸmdE%}x)& 'EPXZ`ei2Kq1'No )%rQ+YzӼ5z_|}9e"I#:5ey`1>[B~֘&CSB#]MfZO韟gY`ƻ4[g}b%~XV!Kkjb<ՙVJeB+yp{d)z]w]xh&W{w:q&=L'CU?%j-LOŹhc!i6׍x ׈PglJ;~$C^A6ȼ4ÚŅQNNU% ô#{^\+6z 6@;BY)!vd˦zdm/̱cSvdGXJ4}M֥ =He H ad% Ơz7 z-"ٜ߭t}Y8^O9ANb6Þ6P׾Z #+]|:}uA(܇Եor,nG@掭.AR9U!s[AwI#$5C-A:}}l3bP7@Ab9sWL6\ZT-el/v˃u:aߝ&dMnN}Y1߬iNq $Cw 7( A]а߱ZAv4d^% ⟳|KVј&iqf@0AL:G(莏&s0UeПogLsj+byvuo%~PWzmϝrʐT%YSpJ”I/mM}ɦ͡ΌtuZ8 f06g]9*D݇]d1_43>deo 2f '$jCq^e;Jcc "Jǎ5\Soes4,ګ۸FD}p[=}NO0(IRK洚|@m,]u}=V+ f*W *}5w ,ý#'Ǵ. d Q6E:KzJs%Մƥvg_%ȼJ&G8.Fq:ɧ# tf $d& 7n<'u*+J/^X]"605| 4P&8,p,gL&\i~0ow7>?}&wd:<.&"6/fyah{'Eli6tv,`g(CD$Imi ²ۭЙI菜0|p챈Օ_σE~aj)s͜&YVVpY:;:ń &!67hp~7m]%x"%J8~Q j;ͩfȬF/U(gwfuX0?ңO۸D_Fj=(Fx֬$#}-|".ԠuYT4V683~}ȉ^@Wbה99Ujꔻ{^8/c?&:6Y,['aDZK2=1Fk\S: ,ISA UNDo ރXx%I:!.0V'U|Mn&5jos.*Bjiɋ!I -nrɊd E$ƘY H?58/$a(*i`Ӧpvu r>Xe<^tm?|o:PMIt`ZgQzSiM.)U[z#I$'@5(R?8ɓݽ N(h|8l$Pl9(#mݔ>-(+mZ ˀR#DƘgASM=br4MlxEqzw 6pu[u~VV-(n"^6׍_m[<4x+U νk?DMxE1Tze}mw0wP>YAb KGisZ^vU"ݾhy.!QaKJ`8# '&bq\|:qGc0HO]: 7zZ0of2X_{]52%2/'V1Fxzɓ-)ZЍu3"c#3s'-泴,;= Vpz6-Jo ]'^gho<*Z Aq6*vOO2i6>A*LMZsΐVQhL:=]#[dy=Gʧ٦#BWW[[ yAtV1f$Ѯ ݢ8D*kl rߺ/mzMa 7msڝi5.\ԝFHrGRp_}@}T&J?/w+z8̼=3W|U̜ypl"W5²"<dmzJx0 -|-E) pؾIbRKfF0\$Jg+ Gw`“4X ;/ ƧݞY> ƚ(GJd`] 9:fq߰ⲱ}W|:-j R5Bk4*smsU(BN"pMm@ȝEҪ&̵f0VgKuE<ݬ]qe'M7|\ҹ9OΡ/gq=]^E\,9Rr_շo, ۖӑwj]n.[zO=ۢuZPѰHUVՂPu-e:9oAQ1c clinical research Archives – Cliniversity https://www.cliniversity.com/tag/clinical-research/ Innovations in Learning Experience - Cliniversity Tue, 19 Aug 2025 03:18:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.4 https://www.cliniversity.com/wp-content/uploads/2025/05/cropped-favicon-Clini-32x32.png clinical research Archives – Cliniversity https://www.cliniversity.com/tag/clinical-research/ 32 32 Top 5 clinical research interview questions & how to answer them with confidence https://www.cliniversity.com/top-5-clinical-research-interview-questions-how-to-answer-them-with-confidence/ https://www.cliniversity.com/top-5-clinical-research-interview-questions-how-to-answer-them-with-confidence/#respond Sat, 03 May 2025 05:20:49 +0000 https://www.cliniversity.com/?p=2869 Are you preparing for interviews in Clinical Research, Pharmacovigilance, or Regulatory Affairs?

In 2025, the life sciences sector is booming, with a growing demand for skilled and industry-ready professionals. Recruiters today seek more than just academic qualifications. They value clarity of thought, communication skills, and practical knowledge that aligns with industry standards.

Whether you’re a fresh graduate in life sciences or a healthcare professional transitioning into research, preparing well for interviews is the key to unlocking great career opportunities.

Here’s your comprehensive guide to succeeding in clinical research interviews, starting with the top 5 frequently asked questions and how to tackle them like a pro.

The post Top 5 clinical research interview questions & how to answer them with confidence appeared first on Cliniversity.

]]>

Top 5 Clinical Research Interview Questions & Sample Answers

1. What is GCP and why is it important?

Answer: Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human participants. Governed by ICH-GCP guidelines, it ensures the safety, rights, and confidentiality of participants while maintaining the integrity and credibility of trial data.

Why interviewers ask this: To assess your knowledge of core clinical research principles and your commitment to ethical practices.

2. What is Pharmacovigilance and why is it important?

Answer: Pharmacovigilance (PV) involves the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems. It’s essential for maintaining drug safety, especially post-marketing.

Key components include:

  • Adverse Event (AE) reporting
  • Signal detection
  • Benefit-risk assessment
  • Risk minimization

Why interviewers ask this: To ensure you grasp the importance of patient safety and real-world drug monitoring.

3. How do you handle discrepancies in clinical data?

Answer: Handling data discrepancies involves a systematic approach:

  • Review source documents and Case Report Forms (CRFs)
  • Raise and manage data queries
  • Follow SOPs and reconciliation protocols
  • Collaborate with trial sites for clarifications
  • Ensure proper documentation

Why interviewers ask this: To evaluate your problem-solving skills, attention to detail, and ability to maintain data integrity.

4. Can you explain the drug approval process in India and the US?

Answer: India:

  • Begins with pre-clinical studies
  • Followed by Phase I to IV clinical trials
  • Submission of data to the DCGI for review and approval

US:

  • Similar clinical phases
  • Regulated by the FDA
  • Requires IND (Investigational New Drug), NDA (New Drug Application), or BLA (Biologics License Application), typically in CTD format

Why interviewers ask this: To check your awareness of national and international regulatory frameworks.

5. Why do you want to work in the pharmaceutical industry?

Answer: The pharmaceutical industry is innovative, fast-paced, and dedicated to improving global health. I am drawn to its dynamic nature, the opportunity to contribute to patient safety, and the potential for continuous learning and career growth.

Why interviewers ask this: To understand your personal motivation and career alignment with the industry.

Career Opportunities in 2025: The Landscape Ahead

The demand for professionals in Clinical Research and Pharmacovigilance is surging. Here’s why:

  • The global pharmacovigilance market is projected to surpass USD 12 billion by 2030, growing at a CAGR of 7%
  • India’s Clinical Trials sector is expected to grow at a rate of 12-15% annually

With increased focus on patient safety and regulatory compliance, trained professionals are more essential than ever.

Why Cliniversity is Your Ideal Training Partner

Cliniversity is committed to helping you become industry-ready. Our programs are curated by professionals and designed to help you learn, practice, and excel in real-world job roles.

Our Offerings Include:

  • Clinical Trial Management
  • Pharmacovigilance
  • Regulatory Affairs
  • Medical Writing
  • Medical Coding

What Makes Us Unique:

  • Flexible online class schedules
  • Live + recorded sessions for better learning
  • Lifetime access to our LMS
  • Hands-on software training (especially for PV)
  • Expert-led interview preparation
  • 100% placement assistance

Ready to Start Your Career in Life Sciences?

If you are passionate about making a difference in healthcare through research, Cliniversity is here to guide you every step of the way.

📞 Call us: 7676838731
🌐 Visit: www.cliniversity.com

Start your journey with Cliniversity today and build a career that makes a real impact.

To your success,
Team Cliniversity

The post Top 5 clinical research interview questions & how to answer them with confidence appeared first on Cliniversity.

]]> https://www.cliniversity.com/top-5-clinical-research-interview-questions-how-to-answer-them-with-confidence/feed/ 0 Why clinical research is the career of the future – a guide for aspiring life science professionals https://www.cliniversity.com/cliniversity-com-blog-why-clinical-research-career-growth/ https://www.cliniversity.com/cliniversity-com-blog-why-clinical-research-career-growth/#respond Fri, 07 Mar 2025 11:21:12 +0000 https://www.cliniversity.com/?p=2809 Did you know that every life-saving drug undergoes rigorous testing before reaching the market? That’s the power of Clinical Research.

Imagine a world where life-saving drugs, breakthrough treatments, and advanced medical technologies are developed without thorough research. Impossible, right? That’s where Clinical Research comes in—it’s the backbone of modern medicine, ensuring that every drug, vaccine, and medical procedure is safe and effective.

The post Why clinical research is the career of the future – a guide for aspiring life science professionals appeared first on Cliniversity.

]]>

Why Clinical Research?

12 Powerful Reasons to Choose This Career

In today’s fast-evolving healthcare landscape, Clinical Research is more than just a career—it’s an opportunity to make an impact while securing a stable future. Here’s why you should consider it.

1️. Unmatched Industry Growth & Global Demand

The Clinical Research market is projected to cross $52 billion globally, creating massive job opportunities in pharmaceutical companies, hospitals, biotech firms, and research organizations.

2️. A Career That Saves Lives

Every new drug, vaccine, or therapy undergoes extensive clinical trials before it reaches patients. As a Clinical Research professional, you play a direct role in improving healthcare worldwide.

3️. High Salary & Career Stability

Unlike many industries that fluctuate with economic downturns, Clinical Research remains recession-proof. Entry-level professionals start at ₹3-6 LPA, while senior experts earn ₹15 LPA+.

4️. No Medical Degree? No Problem!

You don’t need to be a doctor to work in Clinical Research. If you have a background in Life Sciences, Biotechnology, Pharmacy, Nursing, or Allied Health Sciences, you’re already qualified to enter this field.

5️. Work with Global Leaders

Clinical Research opens doors to work with top pharmaceutical and research organizations like Pfizer, Novartis, AstraZeneca, IQVIA, and Parexel.

6️. Diverse Career Paths – Beyond Just Research

From Clinical Trial Management and Pharmacovigilance to Medical Writing and Regulatory Affairs, Clinical Research offers multiple specializations based on your interests and strengths.

7️. Hands-on Learning & Innovation

This field is constantly evolving with AI-driven research, digital trials, and personalized medicine, keeping professionals engaged in cutting-edge healthcare innovations.

8️. Rapid Career Growth

With the right training and certifications, you can climb the ladder quickly—progressing from an entry-level position to a managerial or senior research role within 3-5 years.

9️. Work Anywhere in the World

Clinical Research isn’t just limited to India. The industry has a huge global demand, making it easy to land international opportunities with the right qualifications.

10. Industry Recognition & Accreditation

A career in Clinical Research provides you with globally recognized certifications that boost your professional credibility and increase your hiring potential.

11. Be Part of Groundbreaking Medical Discoveries

This isn’t just a job—it’s a mission. Clinical Research professionals contribute to groundbreaking innovations that shape the future of medicine.

12. Flexible Learning & Career Shifts

Unlike many industries, Clinical Research allows professionals to switch between roles, whether in research, compliance, or corporate leadership, keeping your career dynamic and exciting.

Final Thoughts:

The Future Belongs to Clinical Research Professionals


The demand for skilled Clinical Research professionals is growing like never before. Whether you’re a student exploring career options or a faculty member guiding future healthcare leaders, now is the time to step into this high-impact, high-growth industry.

At Cliniversity, we don’t just teach—we build careers. Join us and become part of a field that’s shaping the future of medicine.

How to Kickstart Your Career in Clinical Research?

Now that you know the benefits of this high-demand career, the next step is getting the right training.

At Cliniversity, we offer world-class Clinical Research training programs that prepare you for the industry with:

  • Comprehensive Curriculum – Covering Clinical Trials, Pharmacovigilance, Regulatory Affairs & Medical Writing
  • Hands-on Projects & Case Studies – Learn real-world applications, not just theory
  • Industry Expert Faculty – Gain insights from professionals working in the field
  • 100% Placement Assistance – Connect with top recruiters for career opportunities
  • Globally Recognized Certifications – Stand out with qualifications that employers trust

🚀 Ready to Take the First Step?

📞 Call/WhatsApp: +91 7676838731
📩 Email: info@cliniversity.com
🌐 Visit: www.cliniversity.com

Your future in Clinical Research starts here. Enroll today & be part of the next big revolution in healthcare!

💬 Have questions? Drop a comment or DM us to learn more!

The post Why clinical research is the career of the future – a guide for aspiring life science professionals appeared first on Cliniversity.

]]> https://www.cliniversity.com/cliniversity-com-blog-why-clinical-research-career-growth/feed/ 0 The power of effective data management in clinical trials https://www.cliniversity.com/the-power-of-effective-data-management-in-clinical-trials/ https://www.cliniversity.com/the-power-of-effective-data-management-in-clinical-trials/#respond Fri, 14 Feb 2025 07:08:57 +0000 https://www.cliniversity.com/?p=2774 In the world of clinical research, data management plays a crucial role in shaping the future of medicine. Accurate, reliable, and well-managed data is the foundation of evidence-based decisions that lead to groundbreaking treatments.

The post The power of effective data management in clinical trials appeared first on Cliniversity.

]]>

💡 Why is Data Management So Important?
📍 Minimizes errors and enhances data integrity
📍 Ensures compliance with strict regulatory guidelines
📍 Strengthens trust in clinical trial outcomes
📍 Facilitates seamless data sharing among researchers and stakeholders

🔹 Key Players in Clinical Data Management
✅ Clinical Data Managers – Oversee the accuracy and reporting of trial data
✅ Clinical Study Administrators – Coordinate documents and ensure compliance
✅ Database Developers – Optimize databases for efficiency and performance
✅ Clinical Data Associates – Collect, validate and process clinical data

📌 Best Practices for Data Management in Clinical Trials
🔹 Establish clear Standard Operating Procedures (SOPs)
🔹 Implement robust data validation and discrepancy management
🔹 Use cutting-edge tools to enhance accuracy and efficiency
🔹 Maintain compliance with industry regulations

At Cliniversity, we are committed to fostering excellence in Clinical Data Management (CDM). Our programs equip professionals with the knowledge and skills to drive data accuracy, compliance, and innovation in clinical trials

In the ever-evolving landscape of clinical research, data management is the backbone of successful trials. Every groundbreaking treatment that reaches the market is backed by meticulously collected, processed, and analyzed data. Without a robust data management framework, clinical trials can suffer from inconsistencies, inaccuracies, and regulatory non-compliance, leading to delays or even failures.

Effective data management not only ensures the credibility of clinical research but also enhances patient safety, regulatory adherence, and research efficiency. In this comprehensive guide, we explore:

✅ The significance of data management in clinical trials
✅ Key team members involved in clinical data management
✅ Best practices for handling clinical trial data
✅ The role of technology and regulatory guidelines
✅ The importance of Standard Operating Procedures (SOPs)
✅ Strategies for data validation and discrepancy management
✅How Cliniversity is shaping the future of clinical research through effective data management

Why is Data Management Crucial in Clinical Trials?

Data management in clinical trials is the systematic process of collecting, cleaning, validating, and storing clinical trial data in compliance with regulatory standards. The integrity of clinical trial data determines the effectiveness and safety of new treatments, making data management a critical component of clinical research.

🔹 Ensures Data Accuracy & Consistency – Errors in clinical data can lead to misleading conclusions, affecting drug approvals and patient safety.
🔹 Regulatory Compliance – Adhering to guidelines from bodies like the FDA, EMA, and ICH ensures trials meet ethical and scientific standards.
🔹 Enhances Decision-Making – Reliable data helps researchers make informed decisions about treatment efficacy and safety.
🔹 Optimizes Data Sharing & Collaboration – Well-structured data allows for seamless information exchange between researchers, sponsors, and regulators.
🔹 Speeds Up Drug Development – Efficient data management shortens trial timelines, reducing costs and accelerating new drug approvals.

Without effective data management, clinical research faces the risk of compromised results, delayed approvals, and wasted resources. That’s why adopting best practices is essential.

Key Team Members in Clinical Data Management

Clinical data management is a multidisciplinary effort that requires collaboration between different professionals. Each role contributes to the accuracy, security, and regulatory compliance of clinical data.

1️⃣ Clinical Data Managers (CDMs)

🔹 Oversee data collection, validation, and reporting.
🔹 Ensure compliance with regulatory guidelines.
🔹 Develop clinical data management tools and methodologies.
🔹 Work with cross-functional teams to maintain data integrity.

2️⃣ Clinical Study Administrators (CSAs)

🔹 Assist in tracking site compliance, performance, and project timelines.
🔹 Maintain and update clinical documents and study records.
🔹 Coordinate data flow and case report forms (CRFs).

3️⃣ Database Developers/Programmers

🔹 Design and develop clinical trial databases.
🔹 Optimize data storage and retrieval efficiency.
🔹 Implement data validation protocols to eliminate errors.

4️⃣ Clinical Data Associates

🔹 Collect, document, and process clinical trial data.
🔹 Ensure adherence to protocols and regulatory requirements.
🔹 Identify data discrepancies and work on resolution.

Together, these professionals ensure that clinical data remains accurate, consistent, and compliant with industry regulations.

Best Practices for Clinical Data Management

To ensure high-quality clinical trial outcomes, organizations must adopt best practices in data management. Here are the top strategies that every clinical research team should implement:

1. Establishing Clear Standard Operating Procedures (SOPs)

Standard Operating Procedures (SOPs) provide clear guidelines for data management processes, ensuring consistency and compliance. Key areas include:

📌 Data Collection – Defines methods for capturing trial data from various sources.
📌 Data Entry – Outlines best practices for manual and electronic data input.
📌 Data Validation – Ensures completeness, accuracy, and consistency.
📌 Data Cleaning – Defines strategies for resolving discrepancies.
📌 Data Archiving – Establishes secure long-term data storage protocols.
📌 Quality Control & Monitoring – Ensures trial data meets regulatory compliance.

A well-documented SOP framework helps organizations maintain data accuracy and integrity throughout the clinical trial process.

2. Utilizing Advanced Data Management Tools

Modern Clinical Trial Management Systems (CTMS) and Electronic Data Capture (EDC) solutions streamline data collection, monitoring, and reporting. Key technologies include:

✅ Cloud-based Clinical Data Management Systems (CDMS) – Enhance accessibility and security.
✅ Artificial Intelligence (AI) & Machine Learning (ML) – Identify patterns, improve data accuracy, and predict potential errors.
✅ Blockchain Technology – Enhances data security and transparency in clinical trials.
✅ Automated Data Validation Tools – Reduce errors and improve compliance.

Leveraging cutting-edge technology minimizes errors and accelerates clinical research.

3. Ensuring Regulatory Compliance

Compliance with global regulatory bodies is critical to ensuring clinical trial data integrity. Some key regulations include:

🔹 FDA (Food and Drug Administration, USA)
🔹 EMA (European Medicines Agency, EU)
🔹 ICH-GCP (International Council for Harmonization – Good Clinical Practice)
🔹 CDISC (Clinical Data Interchange Standards Consortium)

Following these guidelines ensures that clinical trial data meets ethical and scientific standards.

4. Implementing Data Validation & Discrepancy Management

To maintain data quality, organizations must implement rigorous validation and discrepancy management protocols.

📍 Data Validation Plan (DVP) – Defines data accuracy and consistency protocol.
📍 Edit Check Programs – Identify and flag discrepancies in clinical data.
📍 Query Management System – Tracks, resolves, and documents data inconsistencies.

By proactively addressing data discrepancies, organizations can prevent costly delays and inaccuracies in clinical research.

5. Data Security & Confidentiality

Clinical trial data includes sensitive patient information, making data security a top priority. Essential security measures include:

🔒 Role-Based Access Controls (RBAC) – Restricts data access based on user roles.
🔒 Data Encryption – Protects patient data from unauthorized access.
🔒 Audit Trails – Tracks changes and ensures transparency.

Implementing strong security measures helps safeguard patient privacy and maintain regulatory compliance.

How Cliniversity is Transforming Clinical Data Management

At Cliniversity, we recognize the growing demand for high-quality data management professionals in clinical research. Our mission is to equip students and professionals with the skills needed to excel in Clinical Data Management (CDM) and Biostatistics.

🔹 Industry-Relevant Training – Our courses align with global regulatory and industry standards.
🔹 Hands-On Experience – Practical learning with real-world case studies and simulations.
🔹 Expert-Led Curriculum – Learn from experienced professionals in clinical research and data management.
🔹 Career Support – Helping professionals transition into roles in pharmaceuticals, CROs, and healthcare organizations.

If you’re passionate about clinical research and data management, Cliniversity provides the perfect platform to build a rewarding career in this domain.

Conclusion

Data management is the foundation of successful clinical trials. By following best practices, leveraging technology, and adhering to regulatory guidelines, we can ensure data accuracy, compliance, and reliability. High-quality clinical trial data leads to groundbreaking treatments that improve patient lives worldwide.

At Cliniversity, we are committed to fostering a new generation of clinical data experts who will drive the future of clinical research and healthcare innovation.

🚀 Ready to take the next step in your Clinical Data Management career? Connect with us today!

Enroll Today and Transform Your Career!

📞 Contact Us: +917676838731

 Whatsapp:    76768 38731
📧 Email: info@cliniversity.com
🌐 Website: http://www.cliniversity.com

The post The power of effective data management in clinical trials appeared first on Cliniversity.

]]> https://www.cliniversity.com/the-power-of-effective-data-management-in-clinical-trials/feed/ 0 Revolutionizing clinical research: empowering patients as partners for breakthrough outcomes https://www.cliniversity.com/revolutionizing-clinical-research-empowering-patients-as-partners-for-breakthrough-outcomes/ https://www.cliniversity.com/revolutionizing-clinical-research-empowering-patients-as-partners-for-breakthrough-outcomes/#respond Sat, 08 Feb 2025 05:34:33 +0000 https://www.cliniversity.com/?p=2758 Embracing Patient-Centricity in Clinical Research

In today’s dynamic clinical research landscape, the paradigm is shifting from viewing participants as passive subjects to engaging them as active partners in the research journey. At Cliniversity, we believe that putting patients at the center of clinical trials is not only a progressive approach—it is essential for driving meaningful scientific discovery and improving healthcare outcomes.

The post Revolutionizing clinical research: empowering patients as partners for breakthrough outcomes appeared first on Cliniversity.

]]>

Understanding Patient-Centricity

Patient-centricity means designing and executing clinical trials with the patient’s needs, preferences, and experiences at the forefront. Rather than merely collecting data, patient-centric trials actively involve participants in shaping the study design and execution. This collaborative approach fosters transparency, builds trust, and ensures that research findings are closely aligned with real-world scenarios. Recent insights indicate that such an approach can lead to higher engagement and improved overall trial success.

Addressing Traditional Challenges

Traditional clinical trials often struggle with low enrollment rates and high dropout percentages. Many participants find conventional trial protocols burdensome, leading to recruitment hurdles and premature discontinuation. By prioritizing patient convenience and flexibility—through streamlined processes, digital engagement tools, and supportive communication—patient-centric trials help overcome these challenges. Studies have shown that when trials are designed with the participant in mind, recruitment improves and dropout rates decrease significantly.

Benefits for Patients

For patients, a patient-centric approach means empowerment and enhanced care. When patients are involved in trial design, they are more likely to feel valued and in control of their health decisions. This engagement not only improves adherence to protocols but also results in more accurate and comprehensive data collection. Patients benefit from reduced trial burden and a more transparent process, ultimately leading to treatments that better address their needs. Research has demonstrated that patient involvement leads to improved satisfaction and better health outcomes.

Benefits for Researchers

Researchers also gain substantially from adopting patient-centric strategies. Enhanced recruitment and improved retention translate to more robust and reliable data. By actively involving patients, researchers receive timely feedback that can refine study protocols and lead to more precise therapeutic outcomes. The patient’s voice helps in identifying practical challenges and real-world efficacy issues early in the process, thereby streamlining the path from clinical trial to clinical application. This synergy between patients and researchers fosters innovation and ultimately accelerates drug and treatment development.

Creating Patient-Centric Trials

To successfully implement patient-centricity, clinical trials must optimize every aspect of the participant experience. This includes:

  • Optimizing Convenience: Simplifying procedures, using digital platforms for remote monitoring, and ensuring trial protocols are as non-intrusive as possible.
  • Active Listening: Engaging patients in the planning stages, soliciting feedback, and adjusting protocols to address their concerns.
  • Collaborative Decision-Making: Involving patients in key decisions about trial design and execution to ensure that the outcomes truly reflect their needs.

Such practices not only improve data quality but also build a foundation of trust and collaboration between participants and researchers. This approach is revolutionizing clinical trial designs worldwide .

Cliniversity’s Commitment to Patient-Centricity

At Cliniversity, our curriculum and training programs are designed to foster a deep understanding of patient-centric research. We empower our students with hands-on training, real-world case studies, and mentorship from industry experts to ensure that they are well-prepared to lead innovative, patient-focused clinical research. By integrating patient-centric principles into every course, Cliniversity is building a new generation of clinical research professionals dedicated to transforming the industry from within.

Conclusion

Patient-centricity is more than just a modern trend—it represents a fundamental shift in how clinical research is conducted. By engaging patients as active partners, clinical trials can overcome longstanding challenges, improve data integrity, and lead to treatments that are truly reflective of patient needs. At Cliniversity, we are proud to champion this transformative approach, preparing our students to be leaders in a clinical research environment that is as innovative as it is inclusive.

By embracing patient-centricity, we are not only revolutionizing clinical research but also paving the way for a future where every patient’s voice contributes to shaping better healthcare for all.

Cliniversity

Enroll Today and Transform Your Career!

📞 Contact Us: +917676838731

 Whatsapp:    76768 38731
📧 Email: info@cliniversity.com
🌐 Website: http://www.cliniversity.com

The post Revolutionizing clinical research: empowering patients as partners for breakthrough outcomes appeared first on Cliniversity.

]]> https://www.cliniversity.com/revolutionizing-clinical-research-empowering-patients-as-partners-for-breakthrough-outcomes/feed/ 0 The evolving scope of pharmacovigilance: advancing medication safety in 2025 https://www.cliniversity.com/2726-2/ https://www.cliniversity.com/2726-2/#respond Thu, 30 Jan 2025 15:03:56 +0000 https://www.cliniversity.com/?p=2726 Pharmacovigilance, the science of detecting, assessing, understanding, and preventing adverse effects of medical products, is crucial for patient safety. In India, the Pharmacovigilance Programme of India (PvPI), under the Indian Pharmacopoeia Commission (IPC), spearheads these efforts. As of January 2025, several initiatives and programs are in place to enhance pharmacovigilance activities across the country.

The post The evolving scope of pharmacovigilance: advancing medication safety in 2025 appeared first on Cliniversity.

]]>

Upcoming Skill Development Programmes

The IPC has announced the 32nd Skill Development Programme on Pharmacovigilance, scheduled from March 3 to 7, 2025. This online program aims to train healthcare professionals in monitoring and reporting adverse drug reactions (ADRs), thereby strengthening the national pharmacovigilance framework.

Recent Initiatives and Achievements

In 2024, the IPC celebrated the 4th National Pharmacovigilance Week from September 17 to 23. This is focusing on promoting ADR reporting among healthcare professionals and the public. Additionally, the IPC received a Special Recognition Award for Outstanding Contribution to Pharmaceutical Research at the CPHI India Pharma Awards 2024, highlighting its commitment to medicine safety.

Digital Advancements in Pharmacovigilance

The IPC has been proactive in integrating digital tools to streamline pharmacovigilance processes. The launch of the Adverse Drug Monitoring System (ADRMS). Online Portal facilitates efficient ADR reporting and data management. Furthermore, the digitalization of the Indian Pharmacopoeia (IP) 2022 and the introduction of the IP Online Portal enhance accessibility to essential pharmacopoeial information for stakeholders.

Global Collaborations and Training

The IPC continues to engage in international collaborations to align with global pharmacovigilance standards. Notably, the Uzbek Delegation’s visit to the IPC in 2024 underscores the IPC’s role in fostering international partnerships. Moreover, the IPC regularly organizes workshops and training sessions, such as the Workshop-cum-Training for staff of NABH accredited hospitals on Pharmacovigilance held on January 31, 2025. To enhance the competencies of healthcare professionals in pharmacovigilance practices.

Future Directions

Looking ahead, the PvPI (Pharmacovigilance Programme of India) aims to expand its network to include all hospitals, both government and private, across India. The program also plans to implement electronic reporting systems to foster a culture of ADR reporting among healthcare professionals. These initiatives are aligned with the long-term goals of developing a robust pharmacovigilance system in the country.

In conclusion, as of January 2025, India’s pharmacovigilance landscape is marked by significant advancements in training, digital integration, and international collaboration, all aimed at ensuring the safety and efficacy of medical products for patients nationwide.

Cliniversity

Enroll Today and Transform Your Career!

📞 Contact Us: +917676838731

 Whatsapp:    76768 38731
📧 Email: info@cliniversity.com
🌐 Website: http://www.cliniversity.com

The post The evolving scope of pharmacovigilance: advancing medication safety in 2025 appeared first on Cliniversity.

]]> https://www.cliniversity.com/2726-2/feed/ 0